< Back to situations

[ORGANIZATION]

The Lancet

Featured in 2 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US]

Deramiocel DMD trial & FDA panel rejection

2 clusters · 10 sources · last updated

Latest: Capricor Therapeutics' deramiocel fails FDA advisory panel vote despite trial benefits

The FDA advisory committee voted 9‑to‑3 against recommending approval of Capricor Therapeutics’ experimental stem‑cell therapy deramiocel for Duchenne muscular dystrophy‑related cardiomyopathy, reinforcing earlier staff

Also covered in